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Background
Cardiac magnetic resonance (CMR) late gadolinium
enhancement (LGE) and early gadolinium enhancement
(EGE) are powerful diagnostic tools for acute cardio-
myopathies. LGE is associated with impaired prognosis
in ischemic and in chronic non-ischemic cardiomyopa-
thy (NICM), but the impact of gadolinium enhanced
CMR on prognosis in recent onset NICM is less well
established. We performed a systematic review with
metanalysis to investigate the prognostic role of an
abnormal contrast enhanced CMR in patients presenting
with recent onset NICM.
Methods
From January 1994 to July 2014, Pubmed, EMBASE and
additional bibliographic sources were searched for publi-
cations using contrast enhanced CMR (EGE and LGE)
in patients with recent onset NICM, defined as symp-
toms onset within 6 months of presentation, including
myocarditis, acute chest pain syndromes with normal
coronaries, and idiopathic acute cardiomyopathy. We
included articles that assessed total mortality and/or
composite cardiovascular events (mortality plus any
combination of cardioverter defibrillator implantation,
cardiac transplantation, hospitalization or worsening
heart failure) with a follow-up of least 3 months after
the initial presentation. Data were independently
extracted by 2 authors and pooled risk ratios (RR) were
calculated using the DerSimonian and Laird random-
effects method.
Results
Eleven publications (1249 patients) were identified for
the mortality endpoint and 8 (1151 patients) for the
composite endpoint, with an average follow-up varying
from 3 to 56 months. Five studies had myocarditis as
the primary diagnostic hypothesis and seven had non-
ischemic cardiomyopathy. Prevalence of abnormal CMR
varied from 28 to 64%, which was defined by LGE in 9
studies and by EGE or a combination of both in the
remaining studies. Abnormal CMR had a pooled RR of
2.53 (95%CI: 0.87-7.4) for total mortality (figure 1), and
a pooled RR of 2.65 (95%CI: 1.57-4.47) for composite
endpoints (figure 2), with significant heterogeneity,
I2=65.5%;P=0.005, and I2=67.6%;P=0.003, respectively.
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Figure 1 Mortality endpoint
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Conclusions
In patients presenting with recent onset NICM, the pre-
sence of an abnormal contrasted enhanced CMR is asso-
ciated with a statistically significant increased risk ratio
for composite endpoints. These findings may help iden-
tify those patients with a worse prognosis and increased
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Figure 2 Composite endpoint
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